# 24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.

> **NCT02878681** · PHASE4 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Visual Impairment Due to Diabetic Macular Edema

## Interventions

- **DRUG:** Ranibizumab
- **DRUG:** Aflibercept

## Key facts

- **NCT ID:** NCT02878681
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-09
- **Primary completion:** 2017-09
- **Final completion:** 2017-09
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02878681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02878681, "24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02878681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*